Recent Developments in Pharmaceutical Patent Law

Jeremy Cobb, Arnold & Porter

Join us on May 24, 2022 for our next webinar. We anticipate 1.00 General CLE credit in Ohio for this event. 

Our presenter will be Jeremy Cobb from Arnold & Porter. Mr. Cobb will present on Recent Developments in Pharmaceutical Patent Law-Biotherapeutics, Enablement, and Written Description. 

Since the approval of the first antibody therapy in 1986, the focus of drug discovery and development has gradually shifted away from small, well-defined chemical molecules to large, complex therapeutic biologics. Biotherapeutics are now playing an increasingly prominent role in combating diseases like cancer and autoimmune diseases. Recently, the Federal Circuit has issued key opinions that provide guidance as to which patent claims can withstand 35 U.S.C. § 112 enablement or written description challenges. This presentation will provide an analysis of recent Federal Circuit opinions and their implications for biotherapeutic patents going forward.

This webinar will be 60 minutes and will share information on the particulars of law governing patents directed toward pharmaceutical inventions.

Register here by May 20th at 5:00 PM.

About the Speaker:

Jeremy Cobb focuses on patent litigation and matters before the Patent Trial and Appeal Board with an emphasis on small molecule and biological patents. He is a senior associate focused on matters from case inception through trial and appeal. His experience includes arguing motions and claim construction, taking and defending expert and fact depositions, and overseeing case strategy and management. Mr. Cobb also has a deep understanding of pharmaceutical patent practice, including Hatch-Waxman litigation; regulatory exclusivity; patent term extensions; and pharmaceutical life cycle management.

Prior to becoming an attorney, Mr. Cobb designed and developed synthetic routes to active pharmaceutical ingredients and their intermediates at GlaxoSmithKline.